Combo DTx-drug: Clinical & Economic evidence

 DTx-drug combination (‘combo’) is becoming one of the easiest ways for DTx companies to commercialize their products through pharma, as they are still wary of incorporating standalone DTx in their portfolios and building companion DTx from the early days of a drug. This meeting will focus on DTx-drug combinations that act as enhancers of the pharmacotherapy and the evidence needed to get the industry buy-in. More specifically, we will discuss: